Esperion Therapeutics ESPR Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accounts payable?
- Esperion Therapeutics (ESPR) reported accounts payable of $68.41M in Q1 2026.
- How has Esperion Therapeutics's accounts payable changed year-over-year?
- Esperion Therapeutics's accounts payable decreased by 5.0% year-over-year, from $71.99M to $68.41M.
- What is the long-term trend for Esperion Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Esperion Therapeutics's accounts payable has grown at a 4.6% compound annual growth rate (CAGR), from $51.98M to $65.07M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.